Novo Nordisk A/S (NVO)
| Market Cap | 261.50B |
| Revenue (ttm) | 49.58B |
| Net Income (ttm) | 16.30B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.67 |
| PE Ratio | 16.49 |
| Forward PE | 17.79 |
| Dividend | $1.23 (2.04%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 7,141,526 |
| Open | 60.22 |
| Previous Close | 62.33 |
| Day's Range | 59.96 - 60.66 |
| 52-Week Range | 43.08 - 93.80 |
| Beta | 0.36 |
| Analysts | Hold |
| Price Target | 54.25 (-10.3%) |
| Earnings Date | Feb 4, 2026 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for NVO stock is "Hold." The 12-month stock price target is $54.25, which is a decrease of -10.30% from the latest price.
News
Trump's Greenland ambition: stocks that may face tariff shock in 2026
EU stocks are in focus on Jan. 16 after President Donald Trump signalled plans of slapping tariffs on nations resisting Washington's push to acquire Greenland. “We need Greenland for national security...
Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data
Novo Nordisk A/S' (NYSE: NVO) stock is trading higher on Friday as the Wegovy (semaglutide) pill hit 3,071 U.S. prescriptions in the first four days after its launch, Reuters noted, citing IQVIA data.
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch
Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the launch of the company's new GLP-1 pill for obesity in the U.S. In a Friday note, TD ...
Novo Nordisk's Wegovy Weight Loss Shot Approved At Higher Dose in U.K.
The U.K.'s health regulator approved a higher dose of Novo Nordisk's Wegovy weight-loss drug applicable to patients with a body mass index of at least 30.
Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch
Novo Nordisk's Wegovy pill hit 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by analysts on Friday showed, as investors closely watch to see if the firm can ram h...
Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss
Britain's regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.
Novo shares jump 7% ahead of US prescription data for Wegovy pill
Shares of Novo Nordisk rose 7% on Friday, touching their highest level since September, and were among the top gainers in Europe, ahead of U.S. prescription data expected from analysts on the Danish d...
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Novo Nordisk CEO Mike Doustdar said 2026 will be the year of "price pressure" as more GLP-1 supply enters the market and pricing deals take effect. Bristol Myers Squibb CEO Chris Boerner said the comp...
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novo Nordisk flags near-term headwinds in international markets
Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as competition intensifies after losing market exclusivity in several countries.
Novo Nordisk CEO: Wegovy not only reduces your weight, but it also shows cardiovascular benefits
Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.
Novo Nordisk CEO: People have been waiting for a GLP-1 pill
Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.
Novo Nordisk CEO explains why new GLP-1 pill expands access to the weight loss drugs
In a Monday interview with CNBC's Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the pharmaceutical giant's new pill format of its weight loss drug will allow more people to use the medicine. GL...
Expect a Busy Year in Obesity Drugs as New Pills Hit the Market
Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026's first half.
Novo Nordisk sees oral pills capturing over third of GLP-1 market by 2030
Oral weight-loss drugs could make up a third or more of the overall GLP-1 market by 2030, a larger percentage than the company originally anticipated, a Novo Nordisk executive said on Monday.
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs
Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives...
Wegovy just became available in an unexpected place
Days after hitting the market, the new pill version of Novo Nordisk's wildly popular weight-loss drug will be available through Amazon's online pharmacy.
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections...
NEW: Wegovy launches first-ever once-daily weight loss pill
Novo Nordisk executive vice president of U.S. operations Dave Moore discusses the drugmaker's newly launched once-daily oral weight-loss pill on ‘The Claman Countdown.'
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.
Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight-loss pill
Amazon said it now offers Novo Nordisk's Wegovy weight-loss pill through its digital pharmacy service. Novo Nordisk began rolling out its first-ever GLP-1 pill in the U.S. earlier this week.
Amazon Pharmacy offers Novo Nordisk's Wegovy pill
Amazon Pharmacy said on Friday it now offers Novo Nordisk's Wegovy pill through insurance plans as well as through a cash-pay option.
Novo Nordisk: A Pill For Growth
Novo Nordisk is rated Buy, with the FDA-approved Wegovy pill seen as a potential catalyst to reignite growth and recapture market share. NVO faces headwinds from lower pill pricing, potential cannibal...
Novo Nordisk: My Top Pick For 2026
Novo Nordisk is my top opportunity for 2026, driven by multiple catalysts and a compelling valuation. The Wegovy pill's FDA approval, aggressive pricing, and first-mover advantage position NVO to rega...